Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(50.0%)
Phase 4
1(50.0%)
2Total
Phase 3(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07425912Completed

Real-World Evaluation of TouchCare Nano in Pediatric Type 1 Diabetes

Role: collaborator

NCT00418470Phase 4Terminated

Prolonging the Duration of Peripheral Venous Catheters in Cystic Fibrosis People

Role: collaborator

NCT01142830Completed

Incidence of Pain After Craniotomy in Children

Role: collaborator

NCT00720538Phase 3Completed

Thalidomide in Pediatric Inflammatory Bowel Diseases.

Role: collaborator

NCT00531531Completed

Evaluation of the Emission Distance of P. Aeruginosa From the Respiratory Tract of People With Cystic Fibrosis

Role: collaborator

All 5 trials loaded